Part 1: VP-315 3 Day Dosing/Week + Part 2: VP-315 3 Day Dosing/Week - Loading Dose + Part 2: VP-315 3 Day Dosing/Week - No Loading Dose + Part 2: VP-315 2 Day Dosing/Week - Split Dose + Part 2: VP-315 3 Day Dosing/Week - Split Dose
Phase 2Completed 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Basal Cell Carcinoma
Conditions
Basal Cell Carcinoma, Skin Cancer, Cancer of the Skin, Basal Cell, Cancer of the Skin, Carcinoma
Trial Timeline
Feb 1, 2022 → Apr 15, 2024
NCT ID
NCT05188729About Part 1: VP-315 3 Day Dosing/Week + Part 2: VP-315 3 Day Dosing/Week - Loading Dose + Part 2: VP-315 3 Day Dosing/Week - No Loading Dose + Part 2: VP-315 2 Day Dosing/Week - Split Dose + Part 2: VP-315 3 Day Dosing/Week - Split Dose
Part 1: VP-315 3 Day Dosing/Week + Part 2: VP-315 3 Day Dosing/Week - Loading Dose + Part 2: VP-315 3 Day Dosing/Week - No Loading Dose + Part 2: VP-315 2 Day Dosing/Week - Split Dose + Part 2: VP-315 3 Day Dosing/Week - Split Dose is a phase 2 stage product being developed by Verrica Pharmaceuticals for Basal Cell Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT05188729. Target conditions include Basal Cell Carcinoma, Skin Cancer, Cancer of the Skin, Basal Cell.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05188729 | Phase 2 | Completed |
Competing Products
20 competing products in Basal Cell Carcinoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| sonidegib | Sun Pharmaceutical | Pre-clinical | 23 |
| Sonidegib Phosphate Capsules | Sun Pharmaceutical | Approved | 85 |
| Vismodegib | Sun Pharmaceutical | Phase 2 | 52 |
| Cemiplimab Injection [Libtayo] | Sun Pharmaceutical | Phase 2 | 52 |
| Vismodegib + Sonidegib | Sun Pharmaceutical | Pre-clinical | 23 |
| Natural Killer Cell Therapy + Universal Donor Expanded TGF-beta-imprinted NK Cells | Johnson & Johnson | Phase 1 | 33 |
| ABBV-8E12 | AbbVie | Pre-clinical | 23 |
| Pembrolizumab + Vismodegib | Merck | Phase 1/2 | 41 |
| LDE225B + Vehicle | Novartis | Phase 2/3 | 65 |
| verteporfin PDT | Novartis | Phase 3 | 77 |
| Vehicle + LDE225 0.25% + LDE225 0.75% | Novartis | Phase 2 | 52 |
| LDE225 | Novartis | Phase 2 | 52 |
| LDE225 + Placebo | Novartis | Phase 2 | 52 |
| Buparlisib + Sonidegib | Novartis | Phase 2 | 52 |
| LDE225 | Novartis | Pre-clinical | 23 |
| LDE225 0.75% + Vehicle | Novartis | Phase 2 | 52 |
| Vismodegib | Roche | Pre-clinical | 23 |
| ERIVEDGE | Roche | Phase 2 | 52 |
| Placebo + Vismodegib | Roche | Phase 2 | 52 |
| vismodegib | Roche | Phase 2 | 52 |